Sai Parenterals Limited

Extreme earnings volatility: consolidated net profit swung from -₹6.66 Cr (Dec 2025) to ₹7.92 Cr (Jun 2026); OPM ranged from -3.7% to +13.16%. Root cause of this instability and durability of recovery must be verified.

Very high PE of 170.99 suggests market is pricing significant earnings recovery that data has not yet sustained—downside risk if profitability reverts toward Dec 2025 levels.

Poor capital efficiency: ROE of 2.91% indicates capital is generating minimal returns—verify if this reflects cyclical headwinds or structural operational issues.

Material margin drag in consolidated business: standalone OPM reaches 25%, but consolidated OPM only 13%, indicating significant profit leakage in group entities—identify which segments and whether fixable.

Standalone operating margins of 25.29% (Jun 2026) and 23.3% (Mar 2026) demonstrate profitable product lines or customer segments exist; verify which products/segments achieve this and whether margins can be replicated at scale.

Recent recovery from -₹6.66 Cr consolidated loss (Dec 2025) to ₹7.92 Cr profit (Jun 2026) suggests operational correction took hold; confirm if turnaround is sustained across future quarters.

Consolidated revenue is 3.4–3.8× standalone revenue, indicating material intra-group business; if consolidated margins can move from 13% toward standalone levels (25%), significant profit upside would follow.

Parenteral/injectable pharmaceutical demand in India driven by hospital utilization, chronic disease treatment, and outpatient procedures may support volume growth—verify market growth rates and company's competitive position in target segments.